CA Patent

CA3130431A1 — Phosphonoacetate gapmer oligonucleotides

Assigned to Roche Innovation Center Copenhagen AS · Expires 2020-08-27 · 6y expired

What this patent protects

The invention relates to a single stranded antisense gapmer oligonucleotide comprising at least one dinucleoside of formula (I), wherein (A1), (A2) and A are as defined in the description and in the claims. The oligonucleotide according to the invention can be used as a medicamen…

USPTO Abstract

The invention relates to a single stranded antisense gapmer oligonucleotide comprising at least one dinucleoside of formula (I), wherein (A1), (A2) and A are as defined in the description and in the claims. The oligonucleotide according to the invention can be used as a medicament.

Drugs covered by this patent

Patent Metadata

Patent number
CA3130431A1
Jurisdiction
CA
Classification
—
Expires
2020-08-27
Drug substance claim
No
Drug product claim
No
Assignee
Roche Innovation Center Copenhagen AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.